IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 223 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.15 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $68,175 | -74.1% | 10,669 | -32.3% | 0.00% | -100.0% |
| Q1 2022 | $263,000 | -69.2% | 15,768 | -41.6% | 0.00% | -50.0% |
| Q1 2021 | $855,000 | -40.5% | 27,017 | -12.7% | 0.00% | -33.3% |
| Q4 2020 | $1,437,000 | +166.6% | 30,965 | +89.2% | 0.00% | +200.0% |
| Q3 2020 | $539,000 | +19.8% | 16,368 | -0.2% | 0.00% | 0.0% |
| Q2 2020 | $450,000 | +11150.0% | 16,397 | +10831.3% | 0.00% | – |
| Q4 2019 | $4,000 | -99.5% | 150 | -99.7% | 0.00% | -100.0% |
| Q3 2019 | $809,000 | -90.4% | 44,427 | -87.0% | 0.00% | -90.0% |
| Q2 2019 | $8,408,000 | +210100.0% | 342,883 | +74117.1% | 0.02% | – |
| Q1 2019 | $4,000 | 0.0% | 462 | -8.5% | 0.00% | – |
| Q4 2018 | $4,000 | -98.9% | 505 | -98.4% | 0.00% | -100.0% |
| Q3 2018 | $360,000 | -68.7% | 32,000 | -64.4% | 0.00% | -66.7% |
| Q2 2018 | $1,151,000 | +2.8% | 89,911 | +35.7% | 0.00% | 0.0% |
| Q1 2018 | $1,120,000 | +27900.0% | 66,252 | +14209.3% | 0.00% | – |
| Q4 2017 | $4,000 | – | 463 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
| Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
| GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
| Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
| Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
| QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
| Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
| Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
| EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |